

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 15/12, C07K 14/715, 16/46, 19/00, 16/28, C12N 15/62, A61K 39/395, C12N 5/10, 15/85, G01N 33/577, 33/68		A1	(11) International Publication Number: WO 97/25425 (43) International Publication Date: 17 July 1997 (17.07.97)
<p>(21) International Application Number: PCT/US97/00325</p> <p>(22) International Filing Date: 7 January 1997 (07.01.97)</p> <p>(30) Priority Data: 08/585,005 8 January 1996 (08.01.96) US 08/667,197 20 June 1996 (20.06.96) US</p> <p>(71) Applicant: GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).</p> <p>(72) Inventors: BENNETT, Brian; 1332 Oddstar Boulevard, Pacifica, CA 94044 (US). CARTER, Paul, J.; 2074 18th Avenue, San Francisco, CA 94116 (US). CHIANG, Nancy, Y.; 622 Quintara Street, San Francisco, CA 94116 (US). KIM, Kyung, Jit; 622 Beavenue Avenue, Los Altos, CA 94024 (US). MATTHEWS, William; 560 Summit Springs Road, Woodside, CA 94062 (US). RODRIGUES, Maria, L.; 2320 Donegal Avenue, South San Francisco, CA 94080 (US).</p> <p>(74) Agents: HASAK, Janet, E. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
<p>(54) Title: WSX RECEPTOR AND LIGANDS</p> <p>(57) Abstract</p> <p>The WSX receptor and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed, including various uses therefor. Uses for WSX ligands (e.g., anti-WSX receptor agonist antibodies or OB protein) in hematopoiesis are also disclosed.</p>			

BEST AVAILABLE COPY